Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Food and Drug Administration Safety and Innovation Act (FDASIA)

Food and Drug Administration Safety and Innovation Act (FDASIA)

                        FDASIA Title VII Drug Supply Chain Provisions
          FDASIA Title VII Overview
          FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials Home
          Regulatory Information
          Laws Enforced by FDA
          Selected Amendments to the FD&C Act
          Food and Drug Administration Safety and Innovation Act (FDASIA)
          Fact Sheet: Breakthrough TherapiesFood and Drug Administration Safety and Innovation Act (FDASIA) Fact Sheet: Breakthrough Therapies
  
  	
    Share
    Post
    Linkedin

    Email
    PrintOn July 9, 2012 the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed. FDASIA Section 902 provides for a new designation - Breakthrough Therapy Designation.  A breakthrough therapy is a drug:intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition andpreliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug.  All requests for breakthrough therapy designation will be reviewed within 60 days of receipt, and FDA will either grant or deny the request.Please refer to section 902 of FDASIA for more specific information about this provision. Additionally, a Guidance for Industry: Expedited Programs for Serious Conditions––Drugs and Biologics was published on May 30, 2014, providing a single resource for information on FDA’s policies and procedures as well as threshold criteria generally applicable to conclude that a drug is a candidate for one or more of the expedited development and review programs: fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation. .Contact Information:Center for Drug Evaluation and Research (CDER)If your application is reviewed in CDER the CDER Breakthrough Therapy Program Manager is:Miranda Raggio, RN, BSN, MAPhone: 301-796-0700Email: ondeio@fda.hhs.govCenter for Biologics Evaluation and Research (CBER)If your application is reviewed in CBER, for Breakthrough Therapy Designation information contact:Christopher Joneckis, Ph.D., Acting Associate Director for Review ManagementPhone: 240-402-8083Email:   Christopher.Joneckis@fda.hhs.govRelated InformationFrequently Asked Questions: Breakthrough Therapies

                                                                                  Content current as of:
      03/28/2018Food and Drug Administration Safety and Innovation Act (FDASIA)

          
                        FDASIA Title VII Drug Supply Chain Provisions
          FDASIA Title VII Overview
          FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop